Mazdutide

01 · What it is

Mazdutide has better-reported trial numbers than any other unapproved compound in this family, and every one of them comes from a single country.

Two phase 3 trials in Nature ^8,9, a phase 3 trial in JAMA ¹⁶, and a phase 2 trial in Med ¹⁰ all enrolled Chinese adults. The 2026 systematic review and meta-analysis says so in its title: efficacy and safety in predominantly Chinese adults ¹³. That is not a criticism of the trials, which are large, randomised and published in the most demanding journals in medicine. It is a statement about what they can and cannot support, and it is absent from every summary of this compound this guide encountered.

What it is. Mazdutide is a once-weekly glucagon receptor and GLP-1 receptor dual agonist — the same receptor combination as survodutide ^2,16.

The numbers are unusually clean. In the phase 2 trial, 80 participants were randomised to mazdutide 9 mg (n = 60) or placebo (n = 20). At week 24 the mean weight change from baseline was −12.78% on the drug and +1.80% on placebo, a treatment difference of −14.58% ¹⁰. In DREAMS-2, mazdutide beat an active comparator: least-squares mean treatment differences versus dulaglutide of −3.78% for 4 mg and −5.76% for 6 mg, both P < 0.0001 ⁹.

An active-comparator phase 3 win, reported with a number, is rare in this family. Retatrutide has none located. Survodutide’s is a semaglutide arm in a biomarker trial. Cagrilintide’s monotherapy data barely exist. Mazdutide has beaten dulaglutide in a Nature phase 3, and that is a real distinction — against dulaglutide, which is not the strongest comparator available.

On tolerability it also does well. A 2026 network meta-analysis of glucagon-receptor agonists reports that mazdutide demonstrated the most favourable tolerability profile among the investigational agents compared ⁶.

02 · Evidence at a glance

Evidence grade

Early Clinical — multiple reported phase 3 trials; no US marketing authorisation located

What it is

A once-weekly glucagon receptor / GLP-1 receptor dual agonist ^2,16

Population, all located human trials

Chinese adults ^8,9,10,16, stated as “predominantly Chinese” in the pooled analysis ¹³

Phase 2, obesity without diabetes

80 randomised (60 drug, 20 placebo); week 24 weight −12.78% vs +1.80%; difference −14.58% ¹⁰

DREAMS, phase 3, type 2 diabetes

320 participants, mean HbA1c 8.24%, BMI 28.2 kg/m², diabetes duration 1.9 years; 1:1:1 to 4 mg, 6 mg or placebo for 24 weeks ⁸

DREAMS-2, phase 3, active comparator

Versus dulaglutide: LS mean treatment difference −3.78% (4 mg) and −5.76% (6 mg), both P < 0.0001 ⁹

GLORY-2, phase 3, obesity

9 mg in Chinese adults with BMI ≥30; adverse events leading to discontinuation reported ¹⁶, with a research summary ¹⁷ and an editorial ¹⁸

Pooled analysis

4 mg and 6 mg reduced weight and HbA1c versus placebo at moderate certainty of evidence, and outperformed dulaglutide on both; also improved waist circumference, lipids, liver enzymes and uric acid ¹³

Dose-response

Meta-regression β = −0.99 (95% CI −1.81 to −0.16; p = 0.0187) ¹²

Tolerability ranking

Most favourable profile among glucagon-receptor agonists compared ⁶

Heart rate

Increased to a similar extent as GLP-1 monoagonists, which are cardioprotective despite that effect ¹⁹

Kidney

Dual GLP-1R/GCGR agonists including mazdutide reported to provide kidney benefits in type 2 diabetes and CKD; mechanism traced to tubular glucagon receptor activation via V-ATPase ²⁰

Preclinical liver

MASLD mouse model, 12-week high-fat diet then 4 weeks of treatment ⁵

Cardiovascular outcome trial

None located

Trials outside China

None located

03 · Mechanism of action

The same two receptors as survodutide

Mazdutide agonises the GLP-1 receptor and the glucagon receptor ^2,16. The 2026 IUPHAR review that frames glucagon-receptor agonism as a repurposing of a hormone previously treated as the enemy lists mazdutide among the dual agonists built on that idea ².

Two compounds in this family occupy the same receptor pair. That makes them a natural comparison, and the comparison is instructive: survodutide’s programme is multi-regional and liver-focused, mazdutide’s is single-country and broader in indication. Same pharmacology, different development strategy.

The kidney finding is the novel mechanistic result

A 2026 paper in Science Advances reports renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase, framed on the observation that recent clinical trials of dual GLP-1R/GCGR agonists including mazdutide and cotadutide have shown kidney benefits in patients with type 2 diabetes and chronic kidney disease ²⁰.

This is the most specific mechanistic claim in the guide and it runs in the useful direction — from a clinical observation back to a molecular mechanism in a defined tissue compartment. A named transporter in a named nephron segment is a testable account, not a hand-wave. It is also, on the evidence here, an animal and cellular result explaining a human association.

Effects beyond weight and glucose

The pooled analysis reports improvements in waist circumference, lipids, liver enzymes and uric acid ¹³. A separate 2025 review discusses mazdutide among emerging therapies for hyperuricaemia alongside SGLT2 inhibitors and microbiota approaches ¹.

Uric acid is an unusual endpoint for this class and worth flagging as a genuinely distinguishing observation rather than a generic metabolic improvement. It is also a biochemical measure, and no located trial reports gout events.

Preclinical liver work

In a MASLD mouse model induced by 12 weeks of high-fat diet and then treated for 4 weeks, mazdutide’s effects were attributed to modulation of endoplasmic reticulum stress, improved lipid metabolism and reduced inflammation ⁵.

A short treatment window in a diet-induced model, with a mechanism assigned from downstream markers. Standard for the field and a long way from the biopsy-endpoint trials that this project’s liver sections otherwise report.

04 · Key research findings

Type 2 diabetes

DREAMS, 2026. A phase 3 trial randomising 320 participants — mean HbA1c 8.24%, body mass index 28.2 kg/m², diabetes duration 1.9 years — 1:1:1 to weekly subcutaneous mazdutide 4 mg or 6 mg, or placebo, for 24 weeks ⁸.

The population is worth reading closely: a mean diabetes duration of 1.9 years is early disease. That is a favourable setting for a glycaemic agent and not the population in which most diabetes drugs are eventually used.

DREAMS-2, 2026. Against dulaglutide, mazdutide achieved significantly greater weight reduction: least-squares mean treatment differences of −3.78% for 4 mg and −5.76% for 6 mg, both P < 0.0001 ⁹.

Dulaglutide is an approved GLP-1 agonist and a legitimate comparator, though not the strongest one available. Beating it by roughly four to six percentage points is a real result; beating semaglutide or tirzepatide would be a different and harder claim, and no located trial makes it.

Obesity

Phase 2, 2026. Eighty participants with a body mass index of at least 30 kg/m² and without diabetes were randomised to mazdutide 9 mg (n = 60) or placebo (n = 20). At week 24, mean weight change was −12.78% versus +1.80%, a treatment difference of −14.58% ¹⁰.

Eighty participants is small, and the 3:1 randomisation means the placebo arm held twenty people. The effect size is large enough to survive that, and the trial is what it says it is: phase 2.

GLORY-2, 2026. A phase 3 randomised clinical trial of 9-mg mazdutide for weight reduction in Chinese adults with obesity, published in JAMA with a companion research summary ¹⁷ and an accompanying editorial pairing it with orforglipron ¹⁸. Adverse events leading to treatment discontinuation were among the reported outcomes ¹⁶.

This guide has the trial’s design and the fact that discontinuation events were reported; the abstract text retrieved is truncated before the figures. The efficacy and discontinuation numbers are not reported here.

Meta-analyses, 2026. In type 2 diabetes, mazdutide 4 and 6 mg reduced body weight and HbA1c versus placebo at moderate certainty of evidence and outperformed dulaglutide on both, while also improving waist circumference, lipids, liver enzymes and uric acid ¹³. A separate meta-analysis in non-diabetic adults with overweight or obesity found a significant dose effect on meta-regression (β = −0.99, 95% CI −1.81 to −0.16; p = 0.0187) ¹². A further review pooled incretin-based dual and triple agonists — tirzepatide, retatrutide and mazdutide — from a search run to June 2025 ⁴.

Network meta-analyses, 2026. Among glucagon-receptor agonists, mazdutide demonstrated the most favourable tolerability profile ⁶. In the BMJ pipeline network meta-analysis, mazdutide appears among the emerging agents ¹⁴. A 100-point comprehensive evaluation scored long-acting GLP-1 receptor agonists including mazdutide against drug labels, systematic review and real-world data, with semaglutide scoring 76 ³.

The synthesis for this system: the efficacy evidence is randomised, dose-ranged, placebo-and-active-controlled, replicated across phase 2 and phase 3, and consistent in direction. Its weakness is not quality. It is that the entire body of it was generated in one population.

Cardiovascular and kidney

Cardiovascular review, 2026. Clinical studies of glucagon/GLP-1 dual agonists including mazdutide and survodutide have generally found that they increased heart rate to a similar extent as GLP-1 receptor monoagonists, which are cardioprotective despite that chronotropic effect. Mazdutide and survodutide also reduced blood pressure and hyperglycaemia. The same review records that at least one other dual agonist was discontinued, partly for unacceptably large heart-rate increases and QT prolongation ¹⁹.

Both halves belong together and this guide reports both. The heart-rate finding for mazdutide is reassuring in its comparison class; the discontinuation of a different compound is the reason the comparison is being made at all.

Kidney, 2026. Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase, motivated by kidney benefits observed with mazdutide and cotadutide in type 2 diabetes and chronic kidney disease ²⁰.

The synthesis: the cardiovascular and renal signals are favourable and are, so far, mechanistic and observational rather than outcome-trial results. No cardiovascular outcome trial for mazdutide was located.

Commercial literature

A 2026 review presents a patent landscape and therapeutic evolution for the compound ¹¹; broader reviews place it among multi-receptor agonists ⁷ and among late-stage investigational obesity medications ¹⁵.

A patent-landscape review is not evidence about the drug. It is included here to be counted honestly against the publication total rather than allowed to pad it.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects or offer guidance. There is no US product label, because this guide located no US approval.

Animal data. A MASLD mouse model with a 4-week treatment period at three dose levels ⁵. No dedicated toxicology study was retrieved in this search.

Human data. Safety and tolerability were assessed in the phase 2 and phase 3 trials ^8,9,10,16, with adverse events leading to discontinuation among GLORY-2’s reported outcomes ¹⁶. Two meta-analyses address safety ^12,13. The network meta-analysis of glucagon-receptor agonists concluded that mazdutide had the most favourable tolerability profile among the agents compared ⁶.

The tolerability ranking is the compound’s most distinctive clinical claim after the dulaglutide comparison, and it is the kind of finding that could plausibly matter more than effect size, given what discontinuation rates do to real-world effectiveness elsewhere in this family.

Cardiac. Heart rate increased to a similar extent as with GLP-1 receptor monoagonists; blood pressure and hyperglycaemia fell ¹⁹.

What is genuinely unknown. Four items.

Whether any of it generalises. Every located human trial enrolled Chinese adults ^8,9,10,13,16. Body composition, background diet, genetic background and standard of care all differ across populations, and the compound’s effect size in any other population is, on this evidence, untested.

Cardiovascular outcomes. No outcome trial was located. The favourable heart-rate comparison ¹⁹ is a comparison of a physiological variable, not an event count.

Anything beyond 24 weeks. The trials located here ran 24 weeks ^8,10. Durability, maintenance and effects on stopping are unaddressed.

Anything outside a trial. No published analysis located here examines any mazdutide-labelled material obtained outside a clinical trial or an approved supply chain.

07 · US regulatory status

Current as of 7 September 2026. This guide located no United States marketing authorisation for mazdutide. It is described throughout the located literature as investigational or emerging ^2,7,15, and its phase 3 programme is reported in Chinese populations ^8,9,16.

This guide has not consulted FDA, EMA or Chinese regulatory records. The absence of a located US approval is not a confirmed absence of approval in any jurisdiction, and the regulatory position in China in particular is not established by this guide and is flagged for primary-source verification.

Supplying or administering an unapproved drug for human use is unlawful in the United States outside an authorised clinical trial or expanded-access pathway.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. Every located human trial enrolled Chinese adults ^8,9,10,13,16. The pooled analysis states this in its title. No trial in any other population was located. This is the central limitation of the compound’s evidence base and it is routinely omitted when its numbers are quoted.
2. This guide did not establish the compound’s regulatory status in China, where its programme was conducted. That is a material gap in Section 7 and a verification item.
3. The active comparator was dulaglutide ⁹, not semaglutide or tirzepatide. A win against dulaglutide does not position the compound against the current leaders, and no trial doing so was located.
4. GLORY-2’s figures are not reported here ¹⁶; the abstract text retrieved was truncated before them. Full-text retrieval is a verification item.
5. The phase 2 trial randomised 80 people, with 20 on placebo ¹⁰. The effect size is large; the trial is small.
6. The DREAMS population had a mean diabetes duration of 1.9 years ⁸ — early disease, a favourable setting, and not representative of the population in which such drugs are typically used long-term.
7. No cardiovascular or kidney outcome trial was located. The kidney work is a mechanism paper ²⁰; the cardiovascular work is a narrative review of physiological variables ¹⁹.
8. Uric acid, lipid and liver-enzyme improvements are biochemical ¹³. No clinical event endpoint was located for any of them.
9. No dedicated toxicology study was retrieved.
10. No data beyond 24 weeks were located.
11. A patent-landscape review ¹¹ and two general reviews ^7,15 inflate the publication count without adding observations about the drug.
12. Twenty of 47 records were examined, and this guide has read abstracts, not full texts.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Approval status. This guide located no United States marketing authorisation for mazdutide. Supplying or administering an unapproved drug for human use is unlawful in the United States and in most other jurisdictions outside an authorised trial or expanded-access pathway. This guide does not describe how to obtain the compound and takes no position on any supplier.

Products sold under this name. Material sold as mazdutide outside a clinical trial or an approved supply chain has no established relationship to the material used in the studies cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such product. Nothing in the trial evidence described above should be read as applying to it.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide leads with a generalisability limitation that the compound’s own numbers do not advertise.

10 · References

1. Li X, Chen Z, Zhang Y, Fan C, Chen L, Xu X, Chang J, Qiang W, Jiang H, Liu C. Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. Front Endocrinol (Lausanne). 2025 Dec 19;16:1722245. Review.

   PMID 41488145 ↗

2. Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN. IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026 Jan;223:108077. Review.

   PMID 41478576 ↗

3. Chen Q, Chen T, Lin W, Chen X. A clinical comprehensive evaluation of long-acting GLP-1 receptor agonists in type 2 diabetes management. Diabetes Metab Syndr Obes. 2026 Feb 10;19:585436.

   PMID 41710707 ↗

4. Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM, Sia JE, Rahman OU, Ahmad M, Shahid N, Gardezi SA, Joseph KV, Behary Paray N, Zulfiqar E. Incretin-based dual and triple agonists in overweight or obese individuals: a systematic review and meta-analysis. Cardiol Rev. 2026 Feb 19.

   PMID 41711462 ↗

5. Gan L, Duan L, Zheng X. Mazdutide ameliorates metabolic dysfunction-associated steatotic liver disease by modulating endoplasmic reticulum stress, improving lipid metabolism and alleviating inflammation. Pharmaceuticals (Basel). 2026 Feb 26;19(3):371.

   PMID 41901218 ↗

6. Abulehia A, Ayesh H, Ayesh O, Jaber D, Asad T, Itbaisha A, Abugharbieh H, Gharbia R, Abu-Hilal LH, Leon BGC. Comparative efficacy and safety of glucagon receptor agonists on metabolic outcomes: a network meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2026 Mar;9(2):e70187. Review.

   PMID 41787737 ↗

7. Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: the era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabol Open. 2026 Mar 23;30:100463. Review.

   PMID 41948476 ↗

8. Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C, Cheng Z, Cao H, Jiang H, Zhang L, Wang H, Shi B, Li Y, Liu M, Feng B, Xue F, Deng H, Li H, Li L, Li Y, Ma Q, Qian L. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026 Apr;652(8108):174–180.

   PMID 41407859 ↗

9. Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, Jin P, Wang X, Cheng Z, Zhang S, Geng J, Guo Y, Hu H, Ma Q, Li L, Du H, Han-Zhang H, Xue F, Deng H, Qian L, Yang W; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026 Apr;652(8108):181–188.

   PMID 41407860 ↗

10. Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y, Qiu W, Ma Q, Liu Z, Wang Y, Deng H, Du H, Han-Zhang H, Qian L. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes: a phase 2 randomized controlled trial. Med. 2026 May 8;7(5):101063.

    PMID 41875890 ↗

11. Abdul Fasi M. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/glucagon receptor agonist for obesity and type 2 diabetes. Expert Opin Ther Pat. 2026 May;36(5):459–469. Review.

    PMID 41820018 ↗

12. Azam MH, Azam MH, Azam KU, Azam MA, Afridi MK, Waqas SA, Abbas MS, Aminpoor H, Ahmed R. Efficacy and safety of mazdutide in managing overweight and obesity among non-diabetic adults: a meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026 Jun;28(6):4464–4473. Review.

    PMID 41804840 ↗

13. Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, Ahsan A, Dutta D. Efficacy and safety of the dual glucagon-like peptide-1 and glucagon receptor agonist mazdutide in predominantly Chinese adults with obesity and/or type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2026 Jul 6. Review.

    PMID 42410325 ↗

14. Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026 Jul 8;394:e372161.

    PMID 42419792 ↗

15. Savas M, Kuckuck S, Boon MR, van Rossum EFC. Beyond weight loss: multisystem benefits of obesity medications. Lancet Diabetes Endocrinol. 2026 Aug;14(8):678–692. Review.

    PMID 42208956 ↗

16. Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L; GLORY-2 Trial Investigators. Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial. JAMA. 2026 Aug 4;336(5):377–388.

    PMID 42251595 ↗

17. Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: research summary. JAMA. 2026 Aug 4;336(5):e268427. No authors listed. No abstract available.

    PMID 42251596 ↗

18. Gadde KM, Talebloo J, Heymsfield SB. Mazdutide and orforglipron — new evidence in obesity and diabetes. JAMA. 2026 Aug 4;336(5):374–376. No abstract available.

    PMID 42251768 ↗

19. Kushner PR, Michos ED. Cardiovascular effects of glucagon receptor signaling alone and combined with glucagon-like peptide-1 receptor signaling in multiagonists: a narrative review with a translational focus. J Am Heart Assoc. 2026 Aug 4;15(15):e049727. Review.

    PMID 42535526 ↗

20. Qu H, Xu M, Du P, Zhang L, Wang W, Liu X, Zhu J, Tian C, He Q, Li J, Tao Y, Gong Z, Yang Q, Zheng Y, Zheng H. Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase. Sci Adv. 2026 Aug 7;12(32):eaeg2534.

    PMID 42555719 ↗